Our Work
Upcoming Events
Want to stay informed about important policy, market access, and health economics issues? Join us for our monthly sessions returning in January 2026 to learn more!
Insights
We offer personalized insights and strategy, and spotlight data in a compelling way to shape policy, communicate value, secure reimbursement, and drive patient access.
-
FDA’s 2026 Draft Guidance on Payer Communications
FDA’s 2026 draft guidance updates the framework for manufacturer communications with payors, formulary committees, and similar entities. The revised guidance clarifies expectations for drugs and devices, health care economic information, unapproved product communications, and follow-up when previously shared information becomes materially outdated.
-
AI in Market Access: The Real Opportunity Is Better Payer Alignment
AI in market access can help biopharma teams apply payer intelligence earlier and more consistently across evidence, pricing, launch, and access strategy.
-
The U.S. Biopharmaceutical Innovation Ecosystem at Risk: The 20-Year Threat to U.S. Innovation and Cures
A 20-year analysis of how research funding instability, FDA capacity challenges, and pricing policy pressures may affect future medicines, patient access, and U.S. biotech innovation.
Market Access Briefs
A Blend of Core Concepts and Breaking Headlines
-
What Are Drug Compendia and Why Are They Important?
What Are Drug Compendia? Drug compendia are comprehensive references that provide detailed information about pharmaceutical products, including their chemical composition, approved and accepted off-label indications, dosages, side effects, interactions, and other important clinical data. Healthcare professionals, regulatory agencies, and payers rely on compendia when developing treatment plans or determining coverage for a specific product and…
-
Pharmacy Benefit Manager (PBM) Reform
PBM Overview Pharmacy Benefit Managers (PBMs) work with health insurers, large employers and other payers to manage prescription drug benefits. The initial role of PBMs was to negotiate reimbursement rates with drug manufacturers, manage prescription drug claims, and reimburse pharmacies for dispensed medications. Since its inception, the role of the PBMs have evolved over time…
-
Types and Uses of Cost-Effectiveness Models
Cost-Effectiveness Models: A Strategic Tool for Pricing and Market Access In today’s market, clinical efficacy alone is rarely enough to differentiate a product. Payers, health systems, and policy bodies want to know: Is the price justified by the value delivered? Cost-effectiveness modeling provides a structured way to answer that question by connecting clinical outcomes to…